CRNX · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · CRNX
+0.06% · +$0.0500 · Vol 796.7K
Live · updated 12:44:24 ET
Crinetics Pharmaceuticals Inc
Pharmaceuticals
$84.83
Veridion Score
BETAMEDIUM CONF · 5/6 factorsMon Aug 24 · last completed session · daily score · 18h old · CRNX
MethodologyEarnings absence reason unknown
CRNX
Crinetics Pharmaceuticals Inc
Mon Aug 24 · last completed session · daily score · 18h old
BUY BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
65/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 24 · last completed session · daily score · 18h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CRNX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Crinetics Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2018
Employees
594
Country
US
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$84.83
Day high
$84.84
Day low
$84.78
Previous close
$84.78
52W high
$84.84
-0.02% from high
52W low
$30.09
100% of range
Market cap
$9B
EPS
$-4.9800
Beta
-0.44
Shares out
106.1M
Volume
796.7K
0.27× rel vol
Avg volume
3M
VWAP
$84.80
Price history computed in-house
1W
+0.13%
1M
+1.31%
3M
+130.58%
1Y
+181.92%
YTD
+82.23%
SMA 50 $69.87 · above
SMA 200 $49.37 · above
52W position 100%
CRNX overview
Related filings and maps
Public disclosures
Congress activity in CRNX
Official filing ↗
CRNX · Transaction Apr 17, 2025 · Filed May 6, 2025 · $1,001 to $15,000
Crinetics Pharmaceuticals, Inc. - Common Stock · Transaction Mar 19, 2025 · Filed Apr 10, 2025 · $1,001 to $15,000
CRNX · Transaction Jan 29, 2025 · Filed Feb 11, 2025 · $1,001 to $15,000
Crinetics Pharmaceuticals, Inc. - Common Stock · Transaction Sep 25, 2024 · Filed Oct 3, 2024 · $1,001 to $15,000
Federal contracts
CRNX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CRNX in this window.
Lobbying spend
CRNX lobbying filings, year to date.
Registered lobbying filings matched to Crinetics Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CRNX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for CRNX.
Options
Sovereign unlock shows live options positioning for CRNX.